The Latest Cardiac and Vascular News
— Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space; previously served as ESPERION COO — — Succeeds Tim Mayleben, who served as President and CEO for almost a decade and will continue to serve as a senior advisor – ANN ARBOR, […]
Phase 1 healthy volunteer study demonstrates that oral administration of IMB-101 is well tolerated and exhibits predictable pharmacokinetic characteristics Pre-clinical study showed that IMB-101 improves cardiac contractile function and fibrosis post-myocardial infarction, highlighting its therapeutic potential in the context of myocardial ischemia and heart failure BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical […]
AT-01 detected cardiac amyloid in AL and ATTR patients with known cardiac disease with 95% sensitivity AT-01 detected cardiac amyloid in patients with AL or ATTR amyloid with normal levels of serum NT-proBNP AT-01 has the potential to distinguish AL and ATTR amyloidosis based on organ distribution SOUTH SAN FRANCISCO, […]
Mavacamten, a potential first-in-class cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), showed improvement in health status compared to placebo at 30 weeks in EXPLORER-HCM trial Findings of new analysis published simultaneously in The Lancet PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data […]
Minimally-invasive, implant-free technology for heart failure patients studied at 1 and 3 months AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved […]
Continued enrollment progress in Phase 3 REVERSE-IT clinical trial for Bentracimab Signed commercial supply agreement with BioVectra to support development and commercialization of lead product candidate bentracimab Completed underwritten public offering of common stock yielding $60.1 million in net proceeds May 13, 2021 04:00 PM Eastern Daylight Time MALVERN, Pa. […]
BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™, the leading digital technology company in healthcare data management, is pleased to announce the appointment of seven cardiac electrophysiologist professionals as members of the company’s medical advisory board. As PaceMate™ continues forward in its mission to advance efficient digital healthcare solutions through innovative technology and its compassion-driven […]
May 14, 2021 Continuous monitoring provides informed, timely clinical decision making and comprehensive, gap-free patient records in the cath lab and beyond Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, providing […]
– Operating loss decreased vs. Q1 2020 – Net loss increased vs. Q1 2020 – ZanthoSyn® revenues decreased vs. Q1 2020 – Company pursuing multiple funding opportunities HONOLULU, May 14, 2021 /PRNewswire/ — Cardax, Inc. (OTCQB:CDXI) reported its Q1 2021 results. Highlights: Financial Results. Operating loss decreased from $906,031 in Q1 2020 to $771,312 in Q1 2021 […]
WARRINGTON, Pa., May 13, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates. Key Business and Financial Updates Expanded the participating […]
